Alnylam Pharmaceuticals Reports Net Loss of $276 Million in Q2 2023
Company Revenue Reaches $318.8 Million, Marking Significant Growth
Alnylam Pharmaceuticals, Inc. (ALNY), a leading biopharmaceutical company specializing in RNA interference therapeutics, announced its financial results for the second quarter of 2023. The company reported a net loss of $276 million during the quarter, compared to a net loss of $277.4 million in the same period last year. Despite the net loss, Alnylam demonstrated substantial growth in revenue, with total revenues reaching $318.8 million for the second quarter of 2023, compared to $224.8 million in the corresponding period in 2022.
Net Loss Analysis
The second quarter of 2023 saw Alnylam Pharmaceuticals record a net loss of $276 million, representing a slight improvement from the net loss of $277.4 million in the same period the previous year. The net loss per common share for the quarter stood at $2.21, while the weighted-average common shares used to compute basic and diluted net loss per common share were 124,659.
Revenue Growth
